Quotient Sciences and Biorasi Partner to Deliver Fully Integrated Early-Phase Clinical Trial Solutions

Collaboration streamlines transition from first-in-human studies to proof-of-concept

Quotient Sciences, a global drug development, research, and manufacturing accelerator, and Biorasi, an international clinical research organization (CRO), today announced a strategic partnership to offer fully integrated early-phase clinical trial solutions. The collaboration is designed to help biotech and pharmaceutical sponsors accelerate programs from Investigational New Drug (IND) submissions to proof-of-concept (POC), seamlessly transitioning from healthy volunteers into patient populations within first-in-human (FIH) Phase I/IIa trials.

Streamlined, Single-Provider Model

Through this partnership, sponsors gain access to:

• Quotient Sciences’ clinical pharmacology expertise and facilities in Miami (US) and Nottingham (UK), encompassing 230 beds and a large participant database.
• Biorasi’s global patient recruitment network, spanning multiple therapeutic areas including dermatology, neurology, nephrology, cell therapy, and other specialty fields.
• A single contract and unified regulatory submissions, reducing outsourcing complexity and accelerating development timelines.

This integrated approach allows sponsors to conduct hybrid or multi-part protocols—combining healthy volunteer and patient cohorts within a single design—offering speed, flexibility, and scientific rigor while generating early clinical data efficiently.

Leadership Perspectives

Thierry Van Nieuwenhove, CEO of Quotient Sciences, said:

"This partnership reflects our 35-year commitment to accelerating drug development to Proof of Concept. By combining Quotient’s clinical expertise with Biorasi’s patient access network, we enable sponsors to conduct early-phase studies efficiently under a single operational model, while maintaining the highest standards of research and data quality."

Chris O’Brien, CEO of Biorasi, added:

"Biotech and pharma innovators need flexible, reliable solutions to succeed in today’s evolving clinical trial environment. Through this collaboration with Quotient Sciences, we provide sponsors with a simplified, scalable model supporting everything from FIH studies to patient POC, helping new therapies reach patients faster."

Translational Pharmaceutics® and Expanded Services

The collaboration builds on Quotient’s Translational Pharmaceutics®, a disruptive approach that integrates formulation development, drug product manufacturing, and clinical testing, saving up to 12 months and accelerating data-driven decision-making.

The partnership also expands access to adjacent services, including CDMO offerings such as pharmacy compounding, drug product manufacturing, data sciences, and regulatory support.

About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the full development pathway. Recognized with CRO Leadership Awards (2021, 2022, 2024) and CDMO Leadership Awards (2023), Quotient helps sponsors bring molecules to patients faster by bridging silos across drug development capabilities.

About Biorasi

Biorasi is a global CRO delivering speed-to-market strategies for small to mid-sized biotech and biopharma sponsors. With over 20 years of experience, Biorasi operates across dermatology, oncology, neurology, nephrology, and other therapeutic areas, providing reliable, flexible, and accessible solutions for today’s complex clinical trial landscape.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!